Malignant Peripheral Nerve Sheath Tumor (MPNST): Understanding Your Pathology Report

Section Editor: Bibianna Purgina, MD FRCPC
September 16, 2026

A malignant peripheral nerve sheath tumor (MPNST) is a cancer that starts from the cells that surround and protect a nerve. It is a type of sarcoma, which is a cancer that begins in the body’s connective tissues. Older pathology reports may use the names malignant schwannoma, neurofibrosarcoma, or neurogenic sarcoma for the same tumor.

Malignant peripheral nerve sheath tumor usually develops along a medium-sized or large nerve deep in the body. Common locations include the trunk, the arms and legs, and the head and neck. It is a rare cancer, making up roughly 2% to 10% of soft tissue sarcomas. Most people diagnosed are adults, and people with neurofibromatosis type 1 (NF1) tend to be diagnosed at a younger age.

This article explains how pathologists diagnose malignant peripheral nerve sheath tumor and what the grade, size, margins, and stage in your MPNST pathology report mean. Our articles on neurofibroma and schwannoma describe the noncancerous nerve sheath tumors that MPNST must be told apart from.

What causes a malignant peripheral nerve sheath tumor?

Malignant peripheral nerve sheath tumor develops when the support cells lining a nerve accumulate changes in their genes. These changes allow the cells to grow without the normal controls. MPNST arises in three main settings:

Neurofibromatosis type 1 (NF1). About 25% to 50% of MPNSTs develop in people with NF1, an inherited condition caused by a change in the NF1 gene. People with NF1 have an estimated 8% to 13% lifetime risk of developing MPNST. In this setting, the cancer usually grows out of a noncancerous tumor called a plexiform neurofibroma.
Previous radiation therapy. Fewer MPNSTs develop in an area of the body that was treated with radiation years earlier.
No known cause. The remaining MPNSTs occur in people with no inherited condition and no history of radiation. These are called sporadic tumors.

The NF1 gene makes a protein called neurofibromin, which acts as a brake on signals that tell cells to grow. When both copies of the gene stop working in a nerve sheath cell, that brake is lost. Changes in the NF1 gene are found in most MPNSTs, including many sporadic tumors. Additional changes, most often in genes called CDKN2A, SUZ12, and EED, usually occur as a noncancerous neurofibroma becomes a cancer.

This change from a noncancerous tumor to a cancer often happens in steps. Between a plexiform neurofibroma and MPNST, pathologists recognize an in-between stage called an atypical neurofibromatous neoplasm of uncertain biologic potential (ANNUBP). A person with NF1 may have had a biopsy showing ANNUBP before a diagnosis of MPNST.

What are the symptoms of a malignant peripheral nerve sheath tumor?

The most common symptom of a malignant peripheral nerve sheath tumor is a growing lump, which may be painful. Because the tumor starts in a nerve, it can also cause numbness, tingling, or weakness in the part of the body that nerve supplies. Tumors deep in the body may not cause symptoms until they are large.

For people with NF1, a change in an existing neurofibroma can be the first sign of MPNST. Warning signs include rapid growth, new pain that does not go away, and new weakness or numbness.

How is the diagnosis made?

The diagnosis of malignant peripheral nerve sheath tumor is made after a pathologist examines a sample of the tumor under the microscope. The sample is usually obtained by a core needle biopsy, which removes small pieces of the tumor with a needle. In people with NF1, a PET scan may first be used to find the most active part of a large neurofibroma so the biopsy can target that area. Sometimes doctors make the diagnosis only after the whole tumor has been removed.

Under the microscope, MPNST is usually made of long, thin cells arranged in bundles. The tumor cells often look very abnormal, many are dividing, and some areas may show dead tumor tissue called necrosis. Sometimes the pathologist can also see the neurofibroma that the tumor developed from. Because MPNST can look like several other tumors, a small biopsy may not give a final answer. In that case, the report may describe a spindle cell sarcoma and suggest a complete diagnosis after surgery.

Unlike many other sarcomas, MPNST does not have a gene fusion, which is a joining of two separate genes. For this reason, pathologists may use molecular tests such as next-generation sequencing (NGS) to look for fusions. Finding a fusion would point to a different diagnosis, such as synovial sarcoma. A result showing no fusion supports the diagnosis of MPNST when the other findings fit.

Once malignant peripheral nerve sheath tumor is confirmed, imaging tests such as MRI and CT scans show the full size of the tumor and whether it has spread. The lungs are the most common site of MPNST spread, so a chest CT scan is usually part of this assessment. The next section describes the immunohistochemistry tests used to confirm the diagnosis.

Immunohistochemistry

Immunohistochemistry uses antibodies to show which proteins tumor cells make. For malignant peripheral nerve sheath tumor, the test helps confirm that the tumor came from nerve sheath cells. It also helps rule out tumors that can look similar, such as melanoma, synovial sarcoma, and schwannoma. No single stain proves the diagnosis, so the pathologist interprets the results as a whole. Your report may include some of the following:

S100. Normal nerve sheath cells make this protein. In MPNST, S100 is usually positive in only some of the tumor cells, or it is negative. Strong staining in nearly every cell is more typical of schwannoma or melanoma, except in the epithelioid type of MPNST.
SOX10. SOX10 is another nerve sheath protein. In MPNST, it usually shows the same patchy or negative pattern as S100.
H3K27me3. H3K27me3 is a chemical tag on the proteins that package DNA, and it helps keep certain genes switched off. Your report may describe it as “lost” or “retained.” Loss of H3K27me3 is seen in about half of MPNSTs and in almost all MPNSTs that develop after radiation. Loss is uncommon in the tumors that mimic MPNST, so a lost result strongly supports the diagnosis. A retained result does not rule out MPNST, because many MPNSTs keep the tag.
Desmin and myogenin. These muscle proteins are positive in tumors that contain areas resembling skeletal muscle, a type called malignant Triton tumor.
SMARCB1 (INI1). This protein is often lost in the epithelioid type of MPNST.
Melanoma markers. Stains such as Melan-A and HMB-45 are expected to be negative in MPNST. A positive result would suggest melanoma instead.

Not every case of malignant peripheral nerve sheath tumor needs every stain. The pathologist chooses tests based on how the tumor looks and where it is located.

Histologic type

Several types of malignant peripheral nerve sheath tumor are recognized in the World Health Organization (WHO) classification of soft tissue and bone tumors, 5th edition (2020). The type is included in your report because some types behave differently or occur in different groups of people.

Malignant peripheral nerve sheath tumor, not otherwise specified (NOS). This is the conventional and most common type. NOS means the tumor lacks the special features of the other types.
Malignant Triton tumor. This type contains areas that look like skeletal muscle. It is more common in people with NF1 and is associated with a less favorable outcome.
Epithelioid malignant peripheral nerve sheath tumor. In this type, the tumor cells are round rather than long and thin. It is not associated with NF1 and sometimes develops from a schwannoma. Unlike the other types, it usually shows strong S100 and SOX10 staining and retains H3K27me3.

Histologic grade

Histologic grade describes how abnormal the cells of a malignant peripheral nerve sheath tumor look and how quickly they appear to be growing. Most soft tissue sarcomas are graded using the FNCLCC system. Grading MPNST this way is less reliable. The College of American Pathologists (CAP) soft tissue protocol, version 4.2 (2024), states that the value of FNCLCC grade in MPNST is unclear.

For this reason, many pathology reports describe MPNST simply as low-grade or high-grade. Some reports do not include a grade at all, and this is expected.

High grade. Most MPNSTs are high grade. Pathologists use this term when the tumor has 10 or more dividing cells in 10 high-power fields, or 3 to 9 dividing cells together with necrosis. A high-power field is the area seen through the microscope at high magnification.
Low grade. A low-grade MPNST has crowded, abnormal-looking cells like those of ANNUBP, with 3 to 9 dividing cells in 10 high-power fields and no necrosis. Low-grade MPNST is uncommon and usually develops within a neurofibroma in a person with NF1.

If your report does include an FNCLCC grade, the pathologist has added scores for tumor differentiation, the number of dividing cells, and the amount of necrosis. The total score gives the final grade.

Grade 1. Total score of 2 or 3.
Grade 2. Total score of 4 or 5.
Grade 3. Total score of 6 to 8.

For staging purposes, grade 2 and grade 3 tumors are both treated as high grade. Higher-grade tumors are more likely to come back after treatment and to spread to other parts of the body.

Tumor size

Tumor size is the greatest dimension of the malignant peripheral nerve sheath tumor, measured in centimeters (cm). The final size comes from the tumor removed at surgery rather than from a biopsy. If the tumor was removed in pieces, the size may be taken from imaging instead.

For MPNSTs of the trunk, arms, legs, and retroperitoneum (the space behind the abdomen), size determines the tumor stage (pT). Tumors larger than 5 cm are associated with a higher risk of spread and a less favorable outcome. MPNSTs are often large when they are found, especially in people with NF1.

Tumor extension

Tumor extension describes whether a malignant peripheral nerve sheath tumor has grown beyond the nerve where it started and into nearby tissues. MPNST can grow along the nerve and into surrounding fat, muscle, bone, or blood vessels. The pathologist examines the tissue removed with the tumor and reports which structures contain tumor cells.

For tumors in the head and neck, the orbit (the space around the eye), and internal organs, growth into nearby structures raises the tumor stage. For tumors of the trunk, arms, and legs, the stage is based on size alone. Even so, growth into bone, major blood vessels, or other large nerves affects how doctors plan surgery and radiation.

Treatment effect

Some people with malignant peripheral nerve sheath tumor receive radiation therapy, chemotherapy, or both before surgery. This is called neoadjuvant or pre-operative treatment. When this happens, the pathologist estimates what percentage of the removed tumor is non-viable (dead) and what percentage is still viable (alive).

A tumor that is 90% or more non-viable is often considered a strong response to pre-operative treatment. For soft tissue sarcomas, including MPNST, experts have not agreed on a single cut-off that predicts outcome. Your doctors interpret the percentage together with the other findings in your report.

Treatment changes how tumor cells look under the microscope. For this reason, the grade is usually taken from the biopsy done before treatment. If no treatment was given before surgery, the report may say there was no known presurgical therapy.

Lymphovascular invasion

Lymphovascular invasion means that cells from the malignant peripheral nerve sheath tumor are seen inside a small blood vessel or lymphatic channel. These vessels give cancer cells a route to other parts of the body. Current reports may list this finding as “lymphatic and/or vascular invasion.”

Present. Tumor cells were seen inside a vessel. This finding is associated with a higher risk of tumor spread.
Not identified. No tumor cells were seen inside vessels in the tissue examined.

Perineural invasion and spread along the nerve

Perineural invasion describes cancer cells growing around a nerve. For most cancers, it is a separate finding that suggests a higher risk of the cancer coming back. Malignant peripheral nerve sheath tumor is different, because it starts inside a nerve. For this reason, perineural invasion is usually not reported as a separate finding for MPNST.

For MPNST, what matters more is how far the tumor has spread along the nerve. The tumor can extend within the nerve beyond the edge of the lump seen on imaging or at surgery. The surgeon may remove a length of nerve on each side of the tumor, and the pathologist checks the cut ends for tumor cells. These nerve margins are described in the next section.

Surgical margins

A margin is the edge of tissue cut by the surgeon to remove a malignant peripheral nerve sheath tumor. The pathologist examines each margin to see whether tumor cells reach it. For soft tissue sarcomas, margin status is the most important predictor of whether the tumor will come back in the same place.

Negative margin. No tumor cells are seen at the cut edge. The report usually names the closest margin and gives its distance from the tumor.
Close margin. Tumor cells are near the cut edge but do not reach it. Reports often list every margin that is less than 0.5 cm from the tumor.
Positive margin. Tumor cells are present at the cut edge. This means some tumor may remain in the body and raises the risk of the tumor coming back. Further surgery or radiation therapy may be considered.
Nerve margins. These are the cut ends of the nerve the tumor grew from, sometimes called the proximal and distal nerve margins. A positive nerve margin means tumor cells have spread along the nerve to the point where it was cut.

Lymph nodes

Lymph nodes are small immune organs that filter fluid from the tissues. Malignant peripheral nerve sheath tumor rarely spreads to lymph nodes. For this reason, lymph nodes are usually removed only if they look enlarged or suspicious on imaging.

If lymph nodes are examined, the report states how many were examined and how many contain tumor cells. Finding tumor cells in a lymph node is uncommon in MPNST but is associated with a less favorable outcome.

Biomarker and molecular testing

Biomarker testing looks for tumor features that can guide treatment, predict outcomes, or point to an inherited condition. For most people with malignant peripheral nerve sheath tumor, no biomarker test currently selects a specific targeted drug. As of 2026, the FDA has not approved any drug specifically for MPNST. The tests used to confirm the diagnosis, including H3K27me3 staining and fusion testing, are described above.

When MPNST has come back, has spread, or cannot be removed, the tumor may be tested with a broad NGS panel. This test commonly finds changes in NF1, in CDKN2A, and in genes that help control which other genes are switched on. These results do not currently match an approved targeted drug for MPNST, but they may make a person eligible for a clinical trial. Rarely, a panel finds a change targeted by a drug that is approved across many cancer types.

Genetic testing for NF1 is a separate question from tumor testing. A change in the NF1 gene found in the tumor does not by itself mean the change is inherited, because sporadic MPNSTs also have NF1 changes. Features of NF1 include light brown skin patches called café-au-lait spots and multiple neurofibromas. If you have these features or a family history of NF1, your doctor may suggest genetic counseling and a blood test.

Our article What is a hereditary cancer syndrome? explains how inherited gene changes are tested. You can learn more about tumor testing in our Biomarkers and Genetic Testing section.

Pathologic stage (pTNM)

The pathologic stage for malignant peripheral nerve sheath tumor is assigned using the TNM system from the American Joint Committee on Cancer (AJCC), 8th edition. The tumor stage (pT) is based on the tissue removed at surgery, and the nodal stage (pN) describes the lymph nodes. The metastasis stage (M) is usually determined by imaging and is often not included in the pathology report.

If you received treatment before surgery, the stage may begin with the letter “y,” as in ypT2. A stage beginning with “r” describes a tumor that has come back after treatment.

The tumor stage (pT) for MPNST depends on where the tumor started in the body.

Trunk and extremities (chest, back, abdominal wall, arms, and legs):

pT1. The tumor is 5 cm or smaller.
pT2. The tumor is larger than 5 cm but not larger than 10 cm.
pT3. The tumor is larger than 10 cm but not larger than 15 cm.
pT4. The tumor is larger than 15 cm.

Retroperitoneum (the space at the back of the abdomen):

pT1. The tumor is 5 cm or smaller.
pT2. The tumor is larger than 5 cm but not larger than 10 cm.
pT3. The tumor is larger than 10 cm but not larger than 15 cm.
pT4. The tumor is larger than 15 cm.

Head and neck:

pT1. The tumor is 2 cm or smaller.
pT2. The tumor is larger than 2 cm but not larger than 4 cm.
pT3. The tumor is larger than 4 cm.
pT4a. The tumor has grown into the eye socket, the bones of the face, or the base of the skull and its lining. It may instead involve the organs in the center of the neck or the chewing muscles called the pterygoid muscles.
pT4b. The tumor has grown into the brain, surrounds the carotid artery, or has grown into the muscles in front of the spine. A tumor that has spread along a nerve into the brain or spinal cord is also pT4b.

Abdominal and thoracic visceral organs (internal organs such as the stomach, intestines, and lungs):

pT1. The tumor is confined to the organ where it started.
pT2a. The tumor has grown into the organ’s thin outer lining.
pT2b. The tumor has grown beyond the outer lining into the surrounding tissue.
pT3. The tumor has grown into another organ or a nearby structure such as the diaphragm or abdominal wall.
pT4a. Tumor is found in 2 separate sites.
pT4b. Tumor is found in 3 to 5 separate sites.
pT4c. Tumor is found in more than 5 separate sites.

Orbit (the space around the eye):

pT1. The tumor is 2 cm or smaller.
pT2. The tumor is larger than 2 cm and has not grown into the bony walls of the orbit or the eye.
pT3. The tumor, of any size, has grown into the bony walls of the orbit.
pT4. The tumor has grown into the eye or nearby structures such as the eyelid, sinuses, or brain.

A stage of pT0 means no tumor was found in the tissue removed, which can happen after treatment before surgery. If the tumor cannot be assessed, for example because it was removed in many pieces, the report may say that pT was not assigned.

The nodal stage (pN) for MPNST describes whether tumor cells were found in the lymph nodes:

pN0. No tumor cells were found in the lymph nodes examined.
pN1. Tumor cells were found in at least one nearby lymph node.

If no lymph nodes were removed, which is common for MPNST, the report will usually say that pN was not assigned. Older reports may show pNX, but current reporting standards no longer use this term for soft tissue sarcomas.

What is the prognosis?

The outlook for a person with malignant peripheral nerve sheath tumor depends mostly on whether the tumor has spread and whether it can be completely removed. Across published studies, about half of people are alive five years after diagnosis. Reported five-year survival ranges widely, from about 15% to about 66%. These differences reflect the size, location, and stage of the tumors included in each study.

MPNST comes back in the same place in about 4 in 10 people after treatment. When MPNST has spread or cannot be removed, survival is much shorter. In reported series of these patients, half lived longer than about 13 to 15 months and half lived less.

Features associated with the outcome of MPNST include:

Spread at diagnosis. Cancer that has already spread when it is found is the strongest predictor of a less favorable outcome.
Completeness of surgery. Complete removal of the tumor with negative margins offers the best chance of cure and lowers the risk of the tumor coming back.
Tumor size. Larger tumors are associated with shorter survival.
Tumor location. Tumors of the trunk and of the head and neck have a less favorable outcome than tumors of the arms and legs.
Histologic grade. High-grade tumors have a less favorable outcome than low-grade tumors.
NF1. Pooled studies have linked MPNST in people with NF1 to shorter survival. Part of this difference may reflect tumors that are larger and harder to remove.
Malignant Triton tumor. This type has been associated with shorter survival than conventional MPNST.

What happens after the diagnosis?

After a malignant peripheral nerve sheath tumor is confirmed, a team at a sarcoma center usually plans care. The team often includes surgeons, radiation oncologists, and medical oncologists who specialize in sarcoma. The findings in your pathology report, including the grade, size, margins, and stage, help this team decide which options to consider.

Surgery. Complete removal of the tumor with negative margins is the main treatment that can cure MPNST that has not spread. Because the tumor grows from a nerve, part of that nerve may need to be removed. This can cause numbness or weakness, so nerve or muscle reconstruction and rehabilitation may be considered.
Radiation therapy. Radiation may be given before or after surgery, often for large or high-grade tumors. It may also be considered when a margin is close or positive, to lower the risk of the tumor coming back.
Chemotherapy. A combination of doxorubicin and ifosfamide is the chemotherapy most often used when MPNST has spread or cannot be removed. Its benefit after complete removal of a tumor that has not spread is uncertain.
Clinical trials. Several new treatments for MPNST are being studied. Your oncologist can tell you whether a trial is open to you, particularly if the tumor has spread or come back.
Treatment of other neurofibromas. Some people with NF1 use medicines called MEK inhibitors to shrink noncancerous plexiform neurofibromas. They do not treat MPNST.

After treatment for MPNST, follow-up usually includes regular imaging of the area where the tumor started and of the chest. People with NF1 also need ongoing monitoring of their other neurofibromas. Genetic counseling can help relatives understand whether they should be tested for NF1.

Questions to ask your doctor

Was the diagnosis of MPNST made on the biopsy, or only after surgery?
Which type of MPNST do I have: conventional, epithelioid, or malignant Triton tumor?
Is my tumor low grade or high grade? Was an FNCLCC grade assigned?
Was H3K27me3 lost or retained, and which other stains were used?
Did my tumor develop from a neurofibroma?
How large was the tumor, and did it grow into nearby structures?
Were all the margins negative, including the nerve margins? How close was the closest margin?
Was lymphatic or vascular invasion found?
If I had treatment before surgery, what percentage of the tumor was non-viable?
What is my pathologic stage, and has the cancer spread to my lungs or elsewhere?
Should I have genetic counseling or testing for NF1?
Will radiation therapy or chemotherapy be considered in my case?
Would molecular testing of my tumor help find a clinical trial?
What follow-up imaging will I need, and how often?